Inclusion Criteria:

          -  Has a histologically or cytologically confirmed diagnosis of Stage IV: M1a, M1b, or
             M1c non-small cell lung cancer (NSCLC) per the American Joint Committee on Cancer
             (AJCC) Staging Manual, version 8

          -  Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1, as determined by the local site assessment

          -  Has confirmation that epidermal growth factor receptor (EGFR)-, anaplastic lymphoma
             kinase (ALK)-, or reactive oxygen species proto-oncogene 1 (ROS1)-directed therapy is
             not indicated as primary therapy and absence of ALK and ROS1 gene rearrangements

          -  Has provided tumor tissue that demonstrates Programmed Cell Death 1 Ligand 1 (PD-L1)
             expression in ≥1% of tumor cells as assessed by immunohistochemistry (IHC) at a
             central laboratory

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 assessed
             within 7 days prior to randomization

          -  Has a life expectancy of at least 3 months

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and at least one of the following conditions applies:

               -  Is not a woman of childbearing potential (WOCBP)

               -  Is a WOCBP and using a contraceptive method that is highly effective (with a
                  failure rate of <1% per year), with low user dependency or be abstinent from
                  heterosexual intercourse as their preferred and usual lifestyle (abstinent on a
                  long term and persistent basis), during the intervention period and for at least
                  120 days after the last dose of study intervention

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has a known history of an additional malignancy, except if the participant has
             undergone potentially curative therapy with no evidence of that disease recurrence for
             at least 3 years since initiation of that therapy

          -  Has received prior systemic chemotherapy or other targeted or biological
             antineoplastic therapy for their metastatic NSCLC.

               -  Prior treatment with chemotherapy and/or radiation as part of
                  neoadjuvant/adjuvant or chemoradiation therapy for nonmetastatic NSCLC is allowed
                  as long as therapy was completed at least 6 months before the diagnosis of
                  metastatic NSCLC.

               -  Participants must have recovered from all AEs due to previous therapies to Grade
                  ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible.
                  Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone
                  replacement may be eligible.

          -  Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1),
             anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death
             receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or
             co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4
             (CTLA-4), OX-40, CD137)

          -  Has received previous treatment with another agent targeting the T cell immunoreceptor
             with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibition motif (ITIM)
             domains (TIGIT) receptor pathway

          -  Has received radiotherapy within 2 weeks of start of study intervention. Participants
             must have recovered from all radiation-related toxicities, not require
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
             for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system
             (CNS) disease

          -  Has received a live or live-attenuated vaccine within 30 days prior to the first dose
             of study intervention. Administration of killed vaccines is allowed

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study intervention

          -  Has known active or untreated CNS metastases and/or carcinomatous meningitis.
             Participants with previously treated brain metastases may participate provided they
             are radiologically stable for at least 4 weeks by repeat imaging, clinically stable,
             and without requirement of steroid treatment for at least 14 days prior to first dose
             of study intervention

          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab/vibostolimab or pembrolizumab
             and/or any of its excipients

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive
             drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form
             of systemic treatment and is allowed.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study intervention

          -  Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis

          -  Has a known history of interstitial lung disease. Lymphangitic spread of the NSCLC is
             not exclusionary.

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is
             required unless mandated by local health authority

          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection

          -  Has a known psychiatric or substance abuse disorder that would interfere with the
             participant's ability to cooperate with the requirements of the study